Biopharmaceutical company Nordic Nanovector ASA (Oslo:NANOV) said on Tuesday that it has entered into a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a potential treatment for patients with B-cell malignancies.
The collaboration aims to combine Nordic Nanovector's expertise around CD37, a protein present on the surface of B-cell tumour cells, with the US university's expertise in CAR-T cell therapies.
Researchers at the University of Pennsylvania (Penn) will look to combine CD37-targeting molecules (antibodies and antibody fragments) and linkers provided by Nordic Nanovector, with the proprietary CAR-T technologies developed at Penn that can direct CAR-T cells against multiple tumour associated antigens.
Nordic Nanovector has obtained an option to license exclusive worldwide rights to any CD37-targeting CAR-T cells that result from this collaboration for further development.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients